Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

4.2K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.2K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

112
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
112

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

Dynamic Changes in Tumor Burden in Patients Undergoing PSMA RLT.

European urology oncology·2026
Same author

PSA persistence in the PSMA PET era: reassessing a risk factor after radical prostatectomy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Effect of [<sup>68</sup>Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.

The Lancet. Oncology·2026
Same author

Bladder activity of different PSMA PET radioligands and impact of furosemide.

American journal of nuclear medicine and molecular imaging·2026
Same author

Radioligand Therapy Hormone Combinations and the ENZA-p Trial.

European urology focus·2026

Related Experiment Video

Updated: Jun 28, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K

Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals.

Honest Ndlovu1, Kgomotso M G Mokoala1, Ismaheel Lawal2

  • 1Nuclear Medicine Research Infrastructure (NuMeRI), Steve Biko Academic Hospital, Pretoria, South Africa; Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa.

PET Clinics
|April 24, 2024
PubMed
Summary

Novel targeted alpha therapies (TATs) using prostate-specific membrane antigen (PSMA) ligands show promise for treating advanced prostate cancer. [225Ac]Ac-PSMA is a leading candidate, demonstrating potential for improved outcomes and quality of life.

Keywords:
Clinical practicePSMAProstate cancerTargeted alpha therapy[(225)Ac]Ac-PSMA-617

More Related Videos

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies
09:29

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies

Published on: February 12, 2015

17.2K
18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography
09:57

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography

Published on: January 11, 2020

7.4K

Related Experiment Videos

Last Updated: Jun 28, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K
The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies
09:29

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies

Published on: February 12, 2015

17.2K
18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography
09:57

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography

Published on: January 11, 2020

7.4K

Area of Science:

  • Oncology
  • Radiopharmaceutical Therapy
  • Nuclear Medicine

Background:

  • Prostate-specific membrane antigen (PSMA) ligands labeled with alpha-emitting radionuclides are emerging as a promising treatment modality.
  • Targeted alpha therapies (TATs) offer unique physical properties for effective cancer treatment, particularly in advanced stages.

Purpose of the Study:

  • To review the growing interest and potential applications of PSMA-targeted alpha therapies.
  • To highlight the role of [225Ac]Ac-PSMA in prostate cancer treatment and ongoing clinical trials.
  • To explore the broader therapeutic potential of TATs beyond metastatic castrate-resistant prostate cancer (mCRPC).

Main Methods:

  • Literature review of PSMA-targeted alpha therapies.
  • Analysis of clinical data and ongoing phase I trials for [225Ac]Ac-PSMA.
  • Exploration of potential resistance mechanisms and combination therapy strategies.

Main Results:

  • [225Ac]Ac-PSMA is extensively used compassionately and is in phase I trials for prostate cancer.
  • TATs demonstrate favorable antitumor activity and potential to improve quality of life.
  • TATs show promise in various clinical scenarios beyond mCRPC.

Conclusions:

  • PSMA-targeted alpha therapies represent a significant advancement in prostate cancer treatment.
  • Further research and clinical trials are warranted to fully establish the efficacy and safety of TATs.
  • Combination therapies may overcome resistance mechanisms and enhance treatment outcomes.